New cancer treatment? MM-111 antibody uses HER2 target to reach and block HER3

Patients with HER2-positive cancers can have dramatic responses to HER2-targeted drugs but eventually develop resistance to the agents. With that problem in mind, researchers are testing a novel type of antibody called MM-111 in patients with HER2-positive disease who have progressed on standard therapy.

Read the whole article on Science Daily

More from Science Daily